BioFire Diagnostics, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease).
Marcy l'Étoile (France), April 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, released its business review for the three months ended March 31, 2020.
BioFire Defense, a bioMérieux subsidiary, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical laboratories to detect SARS-CoV-2.
bioMérieux has finalized the development of the SARS-COV-2 R-GENE® test. This realtime PCR test is clinically validated on one type of respiratory specimen and will be available at the end of March.
Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Monday, January 20, 2020 in observance of Martin Luther King Jr. Day.
Our partnership with the Fleming Fund will seek to strengthen antimicrobial resistance survillance systems and improve public awareness of AMR in -low and -middle-income countries.
Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on December 24 - 25, 2019 and January 1, 2020 in observance of the upcoming holidays.
An article, published on November 15, 2019 in the Triangle Business Journal, discussed the impact of the new Centers for Medicare and Medicaid Services (CMS) Rules on antimicrobial resistance, hospital antimicrobial stewardship programs, and bioMérieux, Inc.
